Pharma BD Deal Intelligence
Amgen Inc. / Kinetix Pharmaceuticals Inc.
2000 · Acquisition/Merger · $170M · Complete
Announcement Sentiment
75
Strongly positive
Amgen acquired privately-held Kinetix Pharmaceuticals (Massachusetts) in an all-stock transaction valued at ~$170M. Brought small-molecule kinase-inhibitor discovery capability complementing Amgen's biologics-heavy portfolio; oncology and inflammation focus.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Assessment window: 10yr post-close.
Key facts
- Announced Oct 17, 2000
- Closed Oct 17, 2000
- Deal value $170M
- Deal type Acquisition/Merger
- Therapeutic area Oncology, inflammation
- Indications Oncology, inflammation
- Key assets Kinase inhibitor discovery programs
- Mechanism Small-molecule protein kinase inhibitors
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals